Mifobate
Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD) -induced PPARγ transcriptional activity (IC50=140 μM) . Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR) . Mifobate (SR-202) shows antiobesity and antidiabetic effects[1].
Product Specifications
CAS Number
76541-72-5
Product Name Alternative
SR-202
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/mifobate.html
Purity
99.85
Solubility
H2O : 35.87 mg/mL (ultrasonic; warming) |DMSO : 100 mg/mL (ultrasonic)
Smiles
O=P(OC)(OC)OC(C1=CC=C(Cl)C=C1)P(OC)(OC)=O
Molecular Formula
C11H17ClO7P2
Molecular Weight
358.65
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PPARγ
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human Leukocyte Surface Antigen CD47/IAP/OA3 (C-Fc)
